Showing results (831-840 of 1,877) with videos related to

Sort By:
Pageof 188
Immunotherapy|February 7, 2023
Pharmacokinetics and safety of CT-P17 (40 mg/0.4 ml) versus reference adalimumab: randomized study in healthy Japanese adultsMiwa Haranaka, Takanori Tanaka, SungHyun Kim, et al.
Immunotherapy|August 16, 2022
Reduced risk of infections with the intravenous immunoglobulin, IgPro10, in patients at risk of secondary immunodeficiency-related infectionsBetsy J Lahue, Rajiv Mallick, Xiang Zhang, et al.
Immunotherapy|August 31, 2021
Antibody therapy against antibiotic-resistant diarrheagenic Escherichia coli: a systematic reviewSrichandrasekar Thuthikkadu Indhuprakash, Mukunthan Karthikeyan, Gayathri Gopal, et al.
Immunotherapy|February 2, 2023
Targeting CD47 enhanced the antitumor immunity of PD-L1 blockade in B-cell lymphomaYanyang Nan, Xuyao Zhang, Shaofei Wang, et al.
Immunotherapy|February 15, 2023
Excellent response of refractory triple-negative breast cancer to sintilimab plus chemotherapy: a case reportGuojun Yao, Junping Huang, Qu Zhang, et al.
Immunotherapy|February 10, 2026
Impact of antibiotics on survival outcomes and risk of gastritis/colitis in advanced-stage melanoma patients receiving immune checkpoint inhibitor therapyShannon L Bailey, Janmesh D Patel, Thomas Havighurst, et al.
Immunotherapy|March 18, 2025
Optimizing TIL therapy for uveal melanoma: lessons learned and unlearned from cutaneous melanomaShravan Leonard-Murali, Udai S Kammula
Immunotherapy|March 3, 2025
Light-based technologies in immunotherapy: advances, mechanisms and applicationsDavide Frumento, Ștefan Ţălu
Immunotherapy|February 28, 2025
Pharmacokinetics and safety of CT‑P39 via auto-injector are comparable to reference omalizumab via pre-filled syringeTomoko Hasunuma, Clive Grattan, Takashi Eto, et al.
Immunotherapy|January 20, 2025
Role of Hb to RDW ratio in metastatic renal cell carcinoma patients treated with first-line immunotherapy combinationsMatilde Corianò, Alessandro Lazzarin, Michele Maffezzoli, et al.
Pageof 188